Injection drug users (IDUs) constitute 60% of the approximately 5 million people in the U.S. infected with hepatitis C virus (HCV). Up to 90% of HIV-infected IDUs are also infected with HCV. HCV treatment leading to sustained viral response (SVR) is associated with increased survival, but to date IDUs have had poor access to HCV care and their success in HCV treatment has been limited. Although past HCV therapies have been relatively ineffective in genotype-1 infected patients, newer regimens are substantially improved. With direct-acting antiviral agents, HCV treatment delivered within large clinical trials leads to SVR or cure in over 70% of genotype-1 infected patients (including HIV/HCV-coinfected patients), compared to 45% with previous therapies. However, SVR rates are as low as 14% in real-world settings. The majority of patients who fail to achieve SVR will develop drug resistance, but the optimal adherence level to minimize resistance is unknown. If HCV treatment continues to be delivered within current models of care, most IDUs will not only fail treatment and develop resistance, but may transmit resistant viruses to others. Because the life- and costsaving benefits of new HCV treatments will not be realized unless we determine optimal models of care for the majority of HCV-infected patients, we are proposing a randomized controlled trial of three models of care. We have previously developed a multidisciplinary model of HCV care which integrates on-site primary care (including HIV care), substance abuse treatment, psychiatric care, and HCV-related care within opiate agonist treatment clinics. To maximize treatment outcomes, we piloted two models of intensive HCV-related care: directly observed therapy (DOT), and concurrent group therapy (CGT). In our DOT model, pegylated interferon is administered once weekly, and one daily dose of oral medication is administered at the methadone window. In our CGT model, patients initiate HCV treatment within a once weekly treatment group which provides powerful social support to mitigate fears of side effects, promote efficient education, and deliver weekly injections. It is unknown whether either model is better or more cost-effective than standard on-site care. In the proposed study, 150 IDUs (100 HCV-monoinfected and 50 HIV/HCV coinfected) with chronic HCV (genotype 1) will be recruited from methadone clinics and randomized to one of three models of care: DOT;concurrent group treatment;or standard on-site care.
Our specific aims are: 1) To determine whether either of two intensive on-site HCV treatment models (DOT or concurrent group treatment) is more efficacious than standard on-site treatment for enhancing adherence and SVR, and decreasing drug resistance;(2) To determine the incidence and factors associated with the development of drug resistance in IDUs;(3) To perform cost and cost-effectiveness analyses of each model;and (4) To examine the impact of HIV coinfection on adherence and virologic outcomes among HCV-infected IDUs.

Public Health Relevance

Injection drug users (including up to 90% of HIV-infected injection drug users) comprise nearly two-thirds of the 5 million people living with HCV-infection in the United States. Though direct acting antiviral agents targeting HCV have tremendous potential to end the HCV epidemic, few injection drug users ever initiate HCV treatment. To realize the full potential of new HCV therapies, it is essential to investigate care delivery models to improve adherence and maximize the number of injection drug users that are able to be cured.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA034086-02
Application #
8507204
Study Section
Risk, Prevention and Intervention for Addictions Study Section (RPIA)
Program Officer
Denisco, Richard A
Project Start
2012-07-15
Project End
2017-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
2
Fiscal Year
2013
Total Cost
$718,774
Indirect Cost
$220,545
Name
Albert Einstein College of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
110521739
City
Bronx
State
NY
Country
United States
Zip Code
10461
Norton, Brianna L; Akiyama, Matthew J; Zamor, Philippe J et al. (2018) Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice. Infect Dis Clin North Am 32:347-370
Batchelder, A W; Cockerham-Colas, L; Peyser, D et al. (2017) Perceived benefits of the hepatitis C peer educators: a qualitative investigation. Harm Reduct J 14:67
Heo, Moonseong; Litwin, Alain H; Blackstock, Oni et al. (2017) Sample size determinations for group-based randomized clinical trials with different levels of data hierarchy between experimental and control arms. Stat Methods Med Res 26:399-413
Norton, Brianna L; Fleming, Julia; Bachhuber, Marcus A et al. (2017) High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic. Int J Drug Policy 47:196-201
Norton, B L; Beitin, A; Glenn, M et al. (2017) Retention in buprenorphine treatment is associated with improved HCV care outcomes. J Subst Abuse Treat 75:38-42
Grebely, Jason; Bruneau, Julie; Lazarus, Jeffrey V et al. (2017) Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. Int J Drug Policy 47:51-60
Heo, Moonseong; Meissner, Paul; Litwin, Alain H et al. (2017) Preference option randomized design (PORD) for comparative effectiveness research: Statistical power for testing comparative effect, preference effect, selection effect, intent-to-treat effect, and overall effect. Stat Methods Med Res :962280217734584
Norton, Brianna L; Southern, William N; Steinman, Meredith et al. (2016) No Differences in Achieving Hepatitis C Virus Care Milestones Between Patients Identified by Birth Cohort or Risk-Based Screening. Clin Gastroenterol Hepatol 14:1356-60
Grebely, Jason; Haire, Bridget; Taylor, Lynn E et al. (2015) Excluding people who use drugs or alcohol from access to hepatitis C treatments – Is this fair, given the available data? J Hepatol 63:779-82
Batchelder, A W; Peyser, D; Nahvi, S et al. (2015) ""Hepatitis C treatment turned me around:"" Psychological and behavioral transformation related to hepatitis C treatment. Drug Alcohol Depend 153:66-71

Showing the most recent 10 out of 17 publications